Selected research
Industry Research
Streptococcus Agalactiae Antibodies Industry Research Report 2026
Market perspective
The global Streptococcus Agalactiae Antibodies market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Streptococcus Agalactiae Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Streptococcus Agalactiae Antibodies is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Streptococcus Agalactiae Antibodies is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Streptococcus Agalactiae Antibodies include United States Biological, Santa Cruz Biotechnology, Inc., QED Bioscience Inc., OriGene Technologies, Novus Biologicals, MyBioSource.com, LifeSpan BioSciences, GeneTex and Creative Biolabs, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Streptococcus Agalactiae Antibodies market in terms of revenue (US$ million) and, where applicable, sales volume (L), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/L) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Streptococcus Agalactiae Antibodies Market by Company
United States Biological
Santa Cruz Biotechnology, Inc.
QED Bioscience Inc.
OriGene Technologies
Novus Biologicals
MyBioSource.com
LifeSpan BioSciences
GeneTex
Creative Biolabs
Biorbyt
Bio-Rad
Abnova Corporation
Streptococcus Agalactiae Antibodies Segment by Type
Polyclonal
Monoclonal
Streptococcus Agalactiae Antibodies Segment by Application
Research Institutes
Hospitals & Diagnostic Laboratories
Pharmaceutical & Biotechnology
Others
Streptococcus Agalactiae Antibodies Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Streptococcus Agalactiae Antibodies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Streptococcus Agalactiae Antibodies and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Streptococcus Agalactiae Antibodies.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Streptococcus Agalactiae Antibodies manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Streptococcus Agalactiae Antibodies by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Streptococcus Agalactiae Antibodies in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Polyclonal
- Monoclonal
Applications
- Research Institutes
- Hospitals & Diagnostic Laboratories
- Pharmaceutical & Biotechnology
- Others
Companies covered
- United States Biological
- Santa Cruz Biotechnology, Inc.
- QED Bioscience Inc.
- OriGene Technologies
- Novus Biologicals
- MyBioSource.com
- LifeSpan BioSciences
- GeneTex
- Creative Biolabs
- Biorbyt
- Bio-Rad
- Abnova Corporation
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Streptococcus Agalactiae Antibodies Market Size (2021-2032)
- 2.2.2 Global Streptococcus Agalactiae Antibodies Sales (2021-2032)
- 2.2.3 Global Streptococcus Agalactiae Antibodies Market Average Price (2021-2032)
- 2.3 Streptococcus Agalactiae Antibodies by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Polyclonal
- 2.3.3 Monoclonal
- 2.4 Streptococcus Agalactiae Antibodies by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Research Institutes
- 2.4.3 Hospitals & Diagnostic Laboratories
- 2.4.4 Pharmaceutical & Biotechnology
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Streptococcus Agalactiae Antibodies Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Streptococcus Agalactiae Antibodies Sales (L) of Manufacturers (2021-2026)
- 3.3 Global Streptococcus Agalactiae Antibodies Revenue of Manufacturers (2021-2026)
- 3.4 Global Streptococcus Agalactiae Antibodies Average Price by Manufacturers (2021-2026)
- 3.5 Global Streptococcus Agalactiae Antibodies Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Streptococcus Agalactiae Antibodies, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Streptococcus Agalactiae Antibodies, Product Type & Application
- 3.8 Global Manufacturers of Streptococcus Agalactiae Antibodies, Established Date
- 3.9 Global Streptococcus Agalactiae Antibodies Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 United States Biological
- 4.1.1 United States Biological Company Information
- 4.1.2 United States Biological Business Overview
- 4.1.3 United States Biological Streptococcus Agalactiae Antibodies Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 United States Biological Streptococcus Agalactiae Antibodies Product Portfolio
- 4.1.5 United States Biological Recent Developments
- 4.2 Santa Cruz Biotechnology, Inc.
- 4.2.1 Santa Cruz Biotechnology, Inc. Company Information
- 4.2.2 Santa Cruz Biotechnology, Inc. Business Overview
- 4.2.3 Santa Cruz Biotechnology, Inc. Streptococcus Agalactiae Antibodies Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Santa Cruz Biotechnology, Inc. Streptococcus Agalactiae Antibodies Product Portfolio
- 4.2.5 Santa Cruz Biotechnology, Inc. Recent Developments
- 4.3 QED Bioscience Inc.
- 4.3.1 QED Bioscience Inc. Company Information
- 4.3.2 QED Bioscience Inc. Business Overview
- 4.3.3 QED Bioscience Inc. Streptococcus Agalactiae Antibodies Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 QED Bioscience Inc. Streptococcus Agalactiae Antibodies Product Portfolio
- 4.3.5 QED Bioscience Inc. Recent Developments
- 4.4 OriGene Technologies
- 4.4.1 OriGene Technologies Company Information
- 4.4.2 OriGene Technologies Business Overview
- 4.4.3 OriGene Technologies Streptococcus Agalactiae Antibodies Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 OriGene Technologies Streptococcus Agalactiae Antibodies Product Portfolio
- 4.4.5 OriGene Technologies Recent Developments
- 4.5 Novus Biologicals
- 4.5.1 Novus Biologicals Company Information
- 4.5.2 Novus Biologicals Business Overview
- 4.5.3 Novus Biologicals Streptococcus Agalactiae Antibodies Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Novus Biologicals Streptococcus Agalactiae Antibodies Product Portfolio
- 4.5.5 Novus Biologicals Recent Developments
- 4.6 MyBioSource.com
- 4.6.1 MyBioSource.com Company Information
- 4.6.2 MyBioSource.com Business Overview
- 4.6.3 MyBioSource.com Streptococcus Agalactiae Antibodies Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 MyBioSource.com Streptococcus Agalactiae Antibodies Product Portfolio
- 4.6.5 MyBioSource.com Recent Developments
- 4.7 LifeSpan BioSciences
- 4.7.1 LifeSpan BioSciences Company Information
- 4.7.2 LifeSpan BioSciences Business Overview
- 4.7.3 LifeSpan BioSciences Streptococcus Agalactiae Antibodies Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 LifeSpan BioSciences Streptococcus Agalactiae Antibodies Product Portfolio
- 4.7.5 LifeSpan BioSciences Recent Developments
- 4.8 GeneTex
- 4.8.1 GeneTex Company Information
- 4.8.2 GeneTex Business Overview
- 4.8.3 GeneTex Streptococcus Agalactiae Antibodies Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 GeneTex Streptococcus Agalactiae Antibodies Product Portfolio
- 4.8.5 GeneTex Recent Developments
- 4.9 Creative Biolabs
- 4.9.1 Creative Biolabs Company Information
- 4.9.2 Creative Biolabs Business Overview
- 4.9.3 Creative Biolabs Streptococcus Agalactiae Antibodies Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Creative Biolabs Streptococcus Agalactiae Antibodies Product Portfolio
- 4.9.5 Creative Biolabs Recent Developments
- 4.10 Biorbyt
- 4.10.1 Biorbyt Company Information
- 4.10.2 Biorbyt Business Overview
- 4.10.3 Biorbyt Streptococcus Agalactiae Antibodies Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Biorbyt Streptococcus Agalactiae Antibodies Product Portfolio
- 4.10.5 Biorbyt Recent Developments
- 4.11 Bio-Rad
- 4.11.1 Bio-Rad Company Information
- 4.11.2 Bio-Rad Business Overview
- 4.11.3 Bio-Rad Streptococcus Agalactiae Antibodies Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Bio-Rad Streptococcus Agalactiae Antibodies Product Portfolio
- 4.11.5 Bio-Rad Recent Developments
- 4.12 Abnova Corporation
- 4.12.1 Abnova Corporation Company Information
- 4.12.2 Abnova Corporation Business Overview
- 4.12.3 Abnova Corporation Streptococcus Agalactiae Antibodies Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Abnova Corporation Streptococcus Agalactiae Antibodies Product Portfolio
- 4.12.5 Abnova Corporation Recent Developments
5 Global Streptococcus Agalactiae Antibodies Market Scenario by Region
- 5.1 Global Streptococcus Agalactiae Antibodies Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Streptococcus Agalactiae Antibodies Sales by Region: 2021-2032
- 5.2.1 Global Streptococcus Agalactiae Antibodies Sales by Region: 2021-2026
- 5.2.2 Global Streptococcus Agalactiae Antibodies Sales by Region: 2027-2032
- 5.3 Global Streptococcus Agalactiae Antibodies Revenue by Region: 2021-2032
- 5.3.1 Global Streptococcus Agalactiae Antibodies Revenue by Region: 2021-2026
- 5.3.2 Global Streptococcus Agalactiae Antibodies Revenue by Region: 2027-2032
- 5.4 North America Streptococcus Agalactiae Antibodies Market Facts & Figures by Country
- 5.4.1 North America Streptococcus Agalactiae Antibodies Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Streptococcus Agalactiae Antibodies Sales by Country (2021-2032)
- 5.4.3 North America Streptococcus Agalactiae Antibodies Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Streptococcus Agalactiae Antibodies Market Facts & Figures by Country
- 5.5.1 Europe Streptococcus Agalactiae Antibodies Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Streptococcus Agalactiae Antibodies Sales by Country (2021-2032)
- 5.5.3 Europe Streptococcus Agalactiae Antibodies Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Streptococcus Agalactiae Antibodies Market Facts & Figures by Country
- 5.6.1 Asia Pacific Streptococcus Agalactiae Antibodies Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Streptococcus Agalactiae Antibodies Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Streptococcus Agalactiae Antibodies Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Streptococcus Agalactiae Antibodies Market Facts & Figures by Country
- 5.7.1 South America Streptococcus Agalactiae Antibodies Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Streptococcus Agalactiae Antibodies Sales by Country (2021-2032)
- 5.7.3 South America Streptococcus Agalactiae Antibodies Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Streptococcus Agalactiae Antibodies Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Streptococcus Agalactiae Antibodies Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Streptococcus Agalactiae Antibodies Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Streptococcus Agalactiae Antibodies Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Streptococcus Agalactiae Antibodies Sales by Type (2021-2032)
- 6.1.1 Global Streptococcus Agalactiae Antibodies Sales by Type (2021-2032) & (L)
- 6.1.2 Global Streptococcus Agalactiae Antibodies Sales Market Share by Type (2021-2032)
- 6.2 Global Streptococcus Agalactiae Antibodies Revenue by Type (2021-2032)
- 6.2.1 Global Streptococcus Agalactiae Antibodies Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Streptococcus Agalactiae Antibodies Revenue Market Share by Type (2021-2032)
- 6.3 Global Streptococcus Agalactiae Antibodies Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Streptococcus Agalactiae Antibodies Sales by Application (2021-2032)
- 7.1.1 Global Streptococcus Agalactiae Antibodies Sales by Application (2021-2032) & (L)
- 7.1.2 Global Streptococcus Agalactiae Antibodies Sales Market Share by Application (2021-2032)
- 7.2 Global Streptococcus Agalactiae Antibodies Revenue by Application (2021-2032)
- 7.2.1 Global Streptococcus Agalactiae Antibodies Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Streptococcus Agalactiae Antibodies Revenue Market Share by Application (2021-2032)
- 7.3 Global Streptococcus Agalactiae Antibodies Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Streptococcus Agalactiae Antibodies Value Chain Analysis
- 8.1.1 Streptococcus Agalactiae Antibodies Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Streptococcus Agalactiae Antibodies Production Mode & Process
- 8.2 Streptococcus Agalactiae Antibodies Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Streptococcus Agalactiae Antibodies Distributors
- 8.2.3 Streptococcus Agalactiae Antibodies Customers
9 Global Streptococcus Agalactiae Antibodies Analyzing Market Dynamics
- 9.1 Streptococcus Agalactiae Antibodies Industry Trends
- 9.2 Streptococcus Agalactiae Antibodies Industry Drivers
- 9.3 Streptococcus Agalactiae Antibodies Industry Opportunities and Challenges
- 9.4 Streptococcus Agalactiae Antibodies Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst